GC Cell and Checkpoint Therapeutics Advance Collaborative Cancer Research
15. Juli 2024 08:00 ET
|
Checkpoint Therapeutics, Inc
Collaboration explores the potential synergistic effects of Checkpoint’s anti-PD-L1, cosibelimab, in combination with the autologous T cell therapy, Immuncell-LC YONGIN, South Korea and WALTHAM,...